<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227681</url>
  </required_header>
  <id_info>
    <org_study_id>TCSP-01</org_study_id>
    <nct_id>NCT01227681</nct_id>
  </id_info>
  <brief_title>Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease</brief_title>
  <official_title>A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of neuroprotection from
      granulocyte colony-stimulating factor on Parkinson disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is the second most common neurodegenerative disease and the severity
      of PD still progress during the ensuing years. Currently, there is no promising medical or
      surgical treatment to abrogate the disease deterioration. Granulocyte colony-stimulating
      factor (G-CSF), one of hematopoietic growth factors, has been routinely used for hematologic
      disorders and stem cell harvest from normal subject. G-CSF also demonstrated neuroprotection
      for rodents PD model. We hypothesize G-CSF will exert the effectiveness of neuroprotection
      for PD patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in Recruitment
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Performance of Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>2 years</time_frame>
    <description>To assess Unified Parkinson's Disease Rating Scale part III (motor function) scores from baseline Medication-off status to Medication-off status after G-CSF injection one year. Scores of UPDRS Part III ranges from 0 to 108 and higher values indicate worse outcome.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>high dose G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose G-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride (NaCl) 0.9 %</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously</description>
    <arm_group_label>high dose G-CSF</arm_group_label>
    <arm_group_label>low dose G-CSF</arm_group_label>
    <other_name>Filgrastim, Kirin, Japan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride (NaCl) 0.9 %</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hoehn &amp; Yahr stage I~III

          -  Patients with idiopathic Parkinson's disease(PD), who meet the United Kingdom
             Parkinson's Disease Society Brain Bank diagnostic criteria, with a good response to
             levodopa

          -  The onset of PD symptoms must be occurred &gt; = 40 years of age (to exclude YOPD), and
             the patient must have been diagnosed with idiopathic PD &gt; =40 years of age

          -  Patients may have symptoms of wearing OFF and/or levodopa induced dyskinesia

          -  Patients must rate between Hoehn &amp; Yahr stage I to III, when in an OFF medication
             state

          -  Patients must in their optimal medication treatment state, and will not changing their
             medications within 3 months before and after enrollment

        Exclusion Criteria:

          -  Patients who are proved to be Young Onset Parkinson's Disease (YOPD) and/or
             genetically related (e.g. Parkin).

          -  Women of child-bearing potential, pregnant or lactating.

          -  Patients who are proved to have tumor growth and/or malignancy.

          -  Patients with a past (within one year) or present history of psychotic symptoms
             requiring anti- psychotic treatment.

          -  Patients with active symptoms of major depression with suicidal ideation or suicide
             attempt.

          -  Patients with previous brain surgery (including pallidotomy and deep brain
             stimulation).

          -  Patients with significant cognitive impairment ( Mini-Mental State Examination, MMSE &lt;
             24).

          -  Patients who do not sign the inform consent,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin Yuan Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital, Hualien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>July 17, 2014</results_first_submitted>
  <results_first_submitted_qc>March 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2016</results_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Parkinson's disease research center, Tzu Chi Hospital</recruitment_details>
      <pre_assignment_details>No participants were randomized to receive 1.65ug/kg/day of G-CSF and placebo</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-CSF</title>
          <description>3.3ug/kg/day for consecutive 5 days of each 60 day cycle</description>
        </group>
        <group group_id="P2">
          <title>Low Dose G-CSF</title>
          <description>1.65ug/kg/day for consecutive 5 days of each 60 day cycle</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>subcutaneous Normal saline for consecutive 5 days of each 60 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose G-CSF Injection for Parkinson's Disease</title>
          <description>3.3 ug/kg/day for consecutive 5 days of each 60 day cycle</description>
        </group>
        <group group_id="B2">
          <title>Low Dose G-CSF Injection for Parkinson's Disease</title>
          <description>1.65 ug/kg/day for consecutive 5 days of each 60 day cycle</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>normal saline 0.9% injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.25" lower_limit="42" upper_limit="56"/>
                    <measurement group_id="B4" value="49.25" lower_limit="42" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Motor Performance of Unified Parkinson's Disease Rating Scale</title>
        <description>To assess Unified Parkinson's Disease Rating Scale part III (motor function) scores from baseline Medication-off status to Medication-off status after G-CSF injection one year. Scores of UPDRS Part III ranges from 0 to 108 and higher values indicate worse outcome.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF Injection for Parkinson's Disease</title>
            <description>3.3ug/kg/day for consecutive 5 days of each 60 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Motor Performance of Unified Parkinson's Disease Rating Scale</title>
          <description>To assess Unified Parkinson's Disease Rating Scale part III (motor function) scores from baseline Medication-off status to Medication-off status after G-CSF injection one year. Scores of UPDRS Part III ranges from 0 to 108 and higher values indicate worse outcome.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="17" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post G-CSF one year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is significant deterioration of UPDRS part III scores from baseline to post G-CSF injection one year</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-CSF Injection for Parkinson's Disease</title>
          <description>3.3ug/kg/day for consecutive 5 days of each 60 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculo-skeletal soreness</sub_title>
                <description>3/4 participants had soreness during 5 days G-CSF injection period and discomfort can be mitigated by NSAID or Acetaminophen</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Chen Shin-Yuan</name_or_title>
      <organization>Buddhist Tzu Chi General Hospital Hualien</organization>
      <phone>+886-3-8561825 ext 2151</phone>
      <email>william.sychen@msa.hinet.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

